Here are 10 things you should know for Tuesday, July 8:
1. -- U.S. stock futures were pointing to a mixed start for Wall Street as second-quarter earnings season gets underway.
European stocks fell while Asian shares ended the session mixed. Japan's Nikkei 225 index slipped 0.4%.
2. -- The economic calendar in the U.S. on Tuesday includes Consumer Credit for May at 3 p.m. EDT.
3. -- U.S. stocks on Monday declined. The Dow Jones Industrial Average closed 0.26% lower to 17,024.21, remaining just above the psychologically important 17,000 milestone set on Thursday. The S&P 500 slid 0.39% to 1,977.65 and the Nasdaq dropped 0.77% to 4,451.53.
4. -- Samsung said second-quarter operating profit declined 24% from a year earlier to a two-year low.
Top 5 Beverage Stocks To Watch Right Now: TD Ameritrade Holding Corporation(AMTD)
TD Ameritrade Holding Corporation, through its subsidiaries, provides securities brokerage services and technology-based financial services to retail investors, traders, and independent registered investment advisors (RIAs) in the United States. The company?s offerings include TD Ameritrade for self-directed retail investors; TD Ameritrade Institutional, which provides brokerage and custody services to independent RIAs and their clients; thinkorswim that offers a suite of trading platforms serving self-directed and institutional traders, and money managers; and Investools, which provides investor education products and services for stock, option, foreign exchange, futures, mutual fund, and fixed-income investors. Its offerings also include Amerivest, an online advisory service that develops portfolios of exchange-traded funds to enable long-term investors pursue their financial goals; and TD Ameritrade Corporate Services, which provides self-directed brokerage services to employees and executives of corporations. In addition, the company offers various products and services, such as common and preferred stocks; exchange-traded funds; a range of option trades, including complex, multi-leg option strategies; futures trades in various commodities, stock indices, and currencies; and foreign exchange products. Further, it provides mutual funds; treasury, corporate, government agency, and municipal bonds; mortgage-backed securities and certificates of deposit; new issue securities; margin lending; and cash management services. Additionally, the company offers trustee, custodial, and other trust-related services to retirement plans; and cash sweep and deposit account products through third-party relationships. It provides its products and services through the Internet, network of retail branches, mobile trading applications, and interactive voice response and registered representatives via telephone. The company was founded in 1971 and is headquart ered in Omaha, Nebraska.
Advisors' Opinion:- [By Matt Koppenheffer]
For Vanguard, the top-ranked online broker in the world according to this report, that's good news -- a happy customer is a loyal customer. It's likewise good news for competitors like TD AMERITRADE� (NYSE: AMTD ) -- which ranked No. 2 for its thinkorswim service and No. 8 for its main platform -- Charles Schwab� (NYSE: SCHW ) (No. 3), and�Interactive Brokers� (NASDAQ: IBKR ) (No. 4 for its U.S. operations, No. 5 for its offering in Germany).
- [By Maureen Farrell]
By early afternoon, TD Ameritrade (AMTD) said roughly 5% of its daily trading volume came from Twitter.
That's much lower than the volume during Facebook's IPO. Even with the glitches, roughly 22% of TD Ameritrade's volume came from trading in Facebook stock when it debuted on May 18, 2012.
5 Best Sliver Stocks To Own For 2014: EDAP TMS S.A.(EDAP)
EDAP TMS S.A., through its subsidiaries, engages in the development, manufacture, and marketing of minimally invasive medical devices primarily for urological diseases. The company operates in two divisions, High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division involves in the development, manufacture, and marketing of medical devices based on HIFU technology for the minimally invasive destruction of various types of localized tumors. This division offers Ablatherm, a HIFU-based ultrasound guided device for the treatment of organ-confined prostate cancer. Its HIFU technology allows the surgeon to destroy a defined area of diseased tissue without damaging surrounding tissue and organs. This division also engages in the leasing of equipment, as well as the sale of disposables, spare parts, and maintenance services. This division markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. The UDS division engages in the development, manufacture, marketing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, primarily urinary stones and other clinical indications. This division provides lithotripters for the treatment of urinary tract stones by means of ESWL technology. This division manufactures three models of lithotripters: the Sonolith Praktis, the Sonolith i-move, and the Sonolith i-sys. This division also involves in the leasing of lithotripters, as well as the sale of disposables, spare parts, and maintenance services. This division markets and sells its products through its direct sales and service platform, as well as through agents and third-party distributors. The company?s customers include public and private hospitals, urology clinics, and research institutions worldwide. EDAP TMS S.A. was founded in 1979 and is based in Vaulx-en-Velin, France.
Advisors' Opinion:- [By Bryan Murphy]
This isn't going to be a well-received idea, given how bullish the stock appears to be at this time, but EDAP TMS S.A. (NASDAQ:EDAP) is a sell. Up 82% since the end of May, EDAP is ripe for a pullback, and may have reached the bearish pivot point as of today.
- [By John Udovich]
Laparoscopic surgery or minimally invasive surgery (MIS) is a type of surgical technique where�operations in the abdomen are performed through small incisions while small cap stocks ArthroCare Corporation (NASDAQ: ARTC), EDAP TMS S.A. (NASDAQ: EDAP), SafeStitch Medical Inc (OTCBB: SFES) and Arch Therapeutics Inc (OTCBB: ARTH) are all in some way focused on aiding minimally invasive procedures. According to a 2012 report produced by MedMarket Diligence, LLC, approximately 114 million surgical and procedure-based wounds occur annually worldwide,�including�36 million in the US, and perhaps�up to a quarter of these procedures can be described as laparoscopic in nature.�Moreover,�use of the technique is bound to increase�as�it reduces�pain and hemorrhaging plus leads to a�shorter recovery time.
- [By Bryan Murphy]
Last week, yours truly posed the unpopular (though largely ignored) premise that EDAP TMS S.A. (NASDAQ:EDAP) was poised to tumble. It wasn't anything personal, nor was it a judgment call on the merits of the company. It was simply a trading-based call, observing how the rally EDAP was enjoying at the time appeared to be running out of gas, and there was no floor to halt any pullback.
5 Best Sliver Stocks To Own For 2014: OncoMed Pharmaceuticals Inc (OMED)
OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company's anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.
Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.
Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.
The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-bas! ed therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.
Advisors' Opinion:- [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]
The U.S. Food and Drug Administration on Wednesday imposed a partial clinical hold on a second cancer treatment trial by OncoMed Pharmaceuticals Inc.(OMED) The FDA’s action follows a similar hold last Friday on another treatment targeting cancer stem cells.
- [By Jake L'Ecuyer]
Equities Trading UP
OncoMed Pharmaceuticals (NASDAQ: OMED) shot up 8.62 percent to $30.09 after the company initiated Phase 1B trial of WNT-parthway-target antibody. Jefferies lifted the price target on the stock from $27 to $46. - [By Stephen Quickel]
Recently, too, Celgene has formed a strategic partnership with OncoMed (OMED) to develop up to six anti-cancer stem-cell antibodies.
Celgene itself has posted four successive quarters of revenue growth, which is expected to lift annual sales from $5.5 to $6.4 billion for calendar 2013, and to $7.5 billion in 2014. Despite its expanding size, earnings per share are projected to grow by 23.2% a year, by 28 Street analysts following its stock.
- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Tuesday’s session are OncoMed Pharmaceuticals Inc.(OMED), Lexicon Pharmaceuticals Inc.(LXRX) and Krispy Kreme Doughnuts Inc.(KKD)
5 Best Sliver Stocks To Own For 2014: StoneMor Partners L.P.(STON)
StoneMor Partners L.P., together with its subsidiaries, engages in the ownership and operation of cemeteries in the southeast, northeast, and west regions of the United States. It offers funeral and cemetery products and services in the death care industry. The company sells interment rights, caskets, burial vaults, cremation niches, markers, and other cemetery related merchandise; provides opening and closing that is the digging and refilling of burial spaces to install the vault and place the casket into the vault; and various other services, including the installation of other cemetery merchandise and the perpetual care related to interment rights. It also offers various funeral-related services, such as family consultation, the removal of and preparation of remains, and the use of funeral home facilities for visitation. As of December 31, 2011, it operated 274 cemeteries, including 253 own cemeteries in 26 states and Puerto Rico; and owned and operated 69 funeral homes in 18 states and Puerto Rico. StoneMor GP LLC serves as the general partner of the company. StoneMor Partners L.P. was founded in 1999 and is headquartered in Levittown, Pennsylvania.
Advisors' Opinion:- [By Shauna O'Brien]
On Friday, cemetery operator StoneMor Partners L.P. (STON) reported that its net loss for the fourth quarter narrowed from last year, aided by a 6.4% rise in revenue.STON’s Earnings in Brief
STON reported a Q4 net loss of�$3.5 million, compared to a loss of $3.9 million a year ago. Revenue was�$63.1 million, up from $59.3 million last year. For FY2013, the company reported a net loss of�$19.0 million, compared to a loss of $3.0 million in 2012. �The large loss in 2013 was primarily due to�costs related to the early retirement of senior notes. Revenue for the year rose to $246.6 million in 2013, from�$242.6 million in 2012.CEO Commentary
Lawrence Miller, President and CEO of STON commented: “StoneMor closed the year with a solid fourth quarter, showing improvement over the fourth quarter of 2012 in nearly every category,” s
“GAAP revenues and operating income in the fourth quarter of 2013 both improved over the fourth quarter of last year, while such non-GAAP financial measures as production based revenue and adjusted operating profits showed very strong growth, up 17.4% and 73.1% respectively. Driving much of this performance has been the ongoing contributions from acquisitions made in 2012 and 2013. The contributions from acquisitions also helped power a 75.9% increase in our distributable cash flow (non-GAAP) compared to the fourth quarter of 2012.
STON’s Dividend
STON paid its last 60 cent quarterly dividend on February 14. We expect the company to announce its next dividend in April.
�Stock Performance�
StoneMor Partners shares were mostly flat during premarket trading Friday. The stock is down 3.8% YTD.
- [By Dan Caplinger]
On Tuesday, StoneMor Partners (NYSE: STON ) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed knee-jerk reaction to news that turns out to be exactly the wrong move.
- [By Rick Munarriz]
StoneMor Partners (NYSE: STON ) also showed signs of life with its payouts.�The only death-care company structured as a high-yielding limited partnership boosted its quarterly rate from $0.59 per unit to $0.595 per unit. It's the second time in six months that StoneMor -- operator of 276 cemeteries and 92 funeral parlors -- has hiked its distributions.�Why push up daisies when you can also push up your yield?